Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Accounts Payables (2023 - 2025)

Kura Oncology (KURA) has disclosed Accounts Payables for 3 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 241.52% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 million, a 241.52% increase, with the full-year FY2025 number at $5.0 million, up 241.52% from a year prior.
  • Accounts Payables was $5.0 million for Q4 2025 at Kura Oncology, down from $66.8 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $66.8 million in Q3 2025 to a low of $1.5 million in Q4 2024.
  • A 3-year average of $22.0 million and a median of $14.5 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: tumbled 95.65% in 2024, then soared 241.52% in 2025.
  • Kura Oncology's Accounts Payables stood at $33.8 million in 2023, then crashed by 95.65% to $1.5 million in 2024, then skyrocketed by 241.52% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Accounts Payables are $5.0 million (Q4 2025), $66.8 million (Q3 2025), and $1.5 million (Q4 2024).